amyloid antibodies

Data from the CLARITY tri­al ear­li­er this year was sup­posed to be the crown­ing glo­ry of the amy­loid hypoth­e­sis, vin­di­ca­tion for pro­po­nents of this long-held but much-maligned the­o­ry of Alzheimer’s disease.

Yet the results left many feel­ing under­whelmed, and even the study authors noncommittal.

The CLARITY tri­al has many admirable fea­tures. It recruit­ed close to 1800 peo­ple from around the world, pret­ty bal­anced between women and men. While the major­i­ty were white, 17% of the cohort was Asian and 12% Latino.

Choice of pri­ma­ry and sec­ondary out­comes were impec­ca­ble. The pri­ma­ry out­come was the Clin­i­cal Demen­tia Rat­ing sum of box­es (CDR-SB), a score­card of sorts rat­ed by a clin­i­cian across the domains of mem­o­ry, ori­en­ta­tion, prob­lem solv­ing, com­mu­ni­ty affairs, home duties and per­son­al care. Sec­ondary out­comes includ­ed stan­dard mea­sures of glob­al cog­ni­tion, dai­ly func­tion, as well as bio­mark­ers in the brain, from the CSF and blood.

So what hap­pened? [Read more…] about Should doc­tors pre­scribe lecanemab (Leqem­bi) to women? The answer, giv­en avail­able evi­dence, is prob­a­bly No